How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Objective: To extend the knowledge of course of improvement in patients with major depressive disorder (MDD), social anxiety disorder (SAD) or generalised anxiety disorder (GAD) participating in randomised placebo‐controlled trials (RCTs) and to infer the optimal duration of initial escitalopram treatment in clinical practice, after which intervention might be reasonable in case of non‐response. Methods: Post hoc analysis of pooled clinical trial database for escitalopram in MDD (14 studies), GAD (4 studies) and SAD (2 studies). ‘Onset’ of action was defined as a 20% or more decrease from baseline score in disorder‐specific psychopathological rating scales: ‘response’ as a 50% or more decrease from baseline score. Results: In MDD, the probability of responding at week 8 if no onset was apparent at week 2 was 43%; in patients with an onset of effect the probability was nearly 80%. Similar patterns were observed in GAD and SAD. The chance of responding beyond week 4 in MDD, GAD and SAD was 20% or less if no effect had occurred by week 2. Conclusions: The pattern of response in these RCTs suggests that in patients with MDD, GAD or SAD in wider clinical practice, a period of at least 4 weeks is worthwhile before considering further intervention. Copyright © 2009 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Liebowitz, M. R. (2015) · Modern Trends in Pharmacopsychiatry · doi:10.1159/000414022 · Cited by 2,266
Taylor, M. J., Freemantle, N., Geddes, J. R., & Bhagwagar, Z. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.11.1217 · Cited by 406
Zimmerman, M., Mattia, J. I., & Posternak, M. A. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.3.469 · Cited by 382
Lepola, U. M., Loft, H., & Reines, E. H. (2003) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000074988.54339.7c · Cited by 254
Bielski, R. J., Ventura, D., & Chang, C.-C. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0906 · Cited by 178
Montgomery, S. A., Huusom, A. K. T., & Bothmer, J. (2004) · Neuropsychobiology · doi:10.1159/000078225 · Cited by 168
Lader, M., Stender, K., Bürger, V., & Nil, R. (2004) · Depression and Anxiety · doi:10.1002/da.20014 · Cited by 163
Montgomery, S. A., Nil, R., Dürr-Pal, N., Loft, H., & Boulenger, J.-P. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n1009 · Cited by 115
Baldwin, D. S., Huusom, A. K. T., & Mæhlum, E. (2006) · British Journal of Psychiatry · doi:10.1192/bjp.bp.105.012799 · Cited by 114
Self-citation
Research works printed but not linked: 33
- Alexopoulos GS, 2004, Fixed dose of escitalopram (10 mg/day) and a flexible dosing regimen of sertraline (50–200 mg/day) in a randomised, double‐blind comparison in depressed patients, World J Biol Psychiatry, 5, 97
- Alexopoulos GS, 2004, A placebo‐controlled trial of escitalopram and sertraline in the treatment of major depressive disorder, Neuropsychopharmacology, 29, S87
- 10.1017/S1461145705005973 · DOI · Paper page
- 10.1017/S1461145701002565 · DOI · Paper page
- 10.1055/s-2006-946702 · DOI · Paper page
- 10.1080/10401230590932326 · DOI · Paper page
- 10.1185/030079906X115513 · DOI · Paper page
- 10.4088/JCP.v63n0410 · DOI · Paper page
- 10.1185/030079905X65484 · DOI · Paper page
- 10.1002/da.10146 · DOI · Paper page
- 10.1111/j.1600-0447.1985.tb02649.x · DOI · Paper page
- Everitt BS, 2004, Clinical Trials in Psychiatry
- 10.1016/j.jad.2004.11.011 · DOI
- Guy W, 1976, ECDEU Assessment Manual for Psychopharmacology, 76
- 10.1111/j.2044-8341.1959.tb00467.x · DOI · Paper page
- 10.1192/bjp.186.3.222 · DOI · Paper page
- 10.1007/s002130050578 · DOI
- 10.1097/00004850-200307000-00003 · DOI · Paper page
- 10.1002/da.20222 · DOI · Paper page
- 10.1192/bjp.134.4.382 · DOI · Paper page
- 10.1176/ajp.152.10.1500 · DOI · Paper page
- 10.1016/j.jpsychires.2008.02.002 · DOI
- 10.1176/appi.ajp.160.4.734 · DOI · Paper page
- 10.1002/da.20214 · DOI
- 10.4088/JCP.v64n1107 · DOI · Paper page
- 10.1055/s-2007-979551 · DOI · Paper page
- 10.1055/s-2007-979192 · DOI · Paper page
- 10.4088/JCP.v68n0805 · DOI · Paper page
- 10.4088/JCP.v63n0211 · DOI · Paper page
- 10.1097/00004850-199400940-00003 · DOI · Paper page
- 10.1097/00004850-200205000-00001 · DOI · Paper page
- 10.1002/mpr.150 · DOI
- 10.1016/S0022-3956(03)00053-0 · DOI
Cited by
Treatment of anxiety disorders
Bandelow, B., Michaelis, S., & Wedekind, D. (2017) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2017.19.2/bbandelow · Cited by 811
Self-citationBaldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676
“, 2008), escitalopram [I (M) (Baldwin et al., 2009), and with alprazolam, pregabalin and venlafaxine [I (M) (Baldwin et al.”
BackgroundMethodInfluentialSelf-citationBandelow, B., Allgulander, C., Baldwin, D. S., Costa, D. L. D. C., Denys, D., Dilbaz, N., Domschke, K., Eriksson, E., Fineberg, N. A., Hättenschwiler, J., et al. (2023) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2022.2086295 · Cited by 158
Self-citationPharmacotherapy of anxiety disorders: A critical review
Koen, N., & Stein, D. J. (2011) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2011.13.4/nkoen · Cited by 151
Self-citationPharmacotherapy for Anxiety Disorders: From First-Line Options to Treatment Resistance
Melaragno, A. J. (2021) · Focus · doi:10.1176/appi.focus.20200048 · Cited by 50
Metadata
- Authors
- Baldwin, D. S., Stein, D. J., Dolberg, O. T., & Bandelow, B.
- Venue
- Human Psychopharmacology: Clinical and Experimental
- Publisher
- Wiley
- Published
- 2009-03-30
- Volume
- 24
- Issue
- 4
- Pages
- 269-275
- ISSN
- 0885-6222 (ISSN-L)
- 1099-1077
- OpenAlex
- W2151423698
- Cited by
- 61
- References
- 11
- FWCI
- 3.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database. https://app.cochat.ai/papers/10.1002/hup.1019
- The paper
- Baldwin, D. S., Stein, D. J., Dolberg, O. T., & Bandelow, B. (2009). How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database. Human Psychopharmacology: Clinical and Experimental. https://doi.org/10.1002/hup.1019
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.